Evidence map›Paper›PMID 41466566›Full record

ArticleMolecular pharmaceutics2026

Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics.

Parnian Mehinrad, Ahmed Abdelfattah, Tanin Shafaati, Jaber Emami, James Donnelly, Frederick G West, Michael Weinfeld, Afsaneh Lavasanifar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parnian MehinradFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Ahmed AbdelfattahFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Tanin ShafaatiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Jaber EmamiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
James DonnellyDepartment of Chemistry, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Frederick G WestDepartment of Chemistry, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Michael WeinfeldDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0002-8773-1425
Afsaneh LavasanifarFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0001-5108-7124

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of ERCC1/XPF, a heterodimeric enzyme complex with endonuclease activity that participates in the repair of DNA inter- and intrastrand cross-links, is expected to make cells sensitive to DNA damage by platinum-based chemotherapeutics. Here we report on repurposing a clinically used antimalaria drug, pyronaridine (PYD), as a novel inhibitor of ERCC1/XPF for the sensitization of colorectal cancer cells (CRC) to platinum drugs. We have developed a liposomal formulation of PYD to make the chemosensitizing activity of this ERCC1/XPF inhibitor more specific to the tumor site. Liposomal PYD was optimized by changing the lipid composition and the pH gradient system within the liposomes. Prepared formulations were characterized for their average diameter, PYD encapsulation, and

Indexed as

Antineoplastic AgentsColorectal NeoplasmsDNA-Binding ProteinsEndonucleasesLiposomesNaphthyridinesCell Line, TumorDrug RepositioningHCT116 CellsHumansOrganoplatinum CompoundsOxaliplatinAntineoplastic AgentsDNA-Binding ProteinsEndonucleasesERCC1 protein, humanLiposomesNaphthyridinesOrganoplatinum CompoundsOxaliplatinxeroderma pigmentosum group F proteincancerDNA repairERCC1/XPFnanomedicineplatinum chemotherapy

Identifiers

PMID41466566
PMCPMC12869475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.